Short answer
Johnson & Johnson (JNJ) filed an 8-K current report with the SEC on April 14, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Q1 fiscal 2026 sales and earnings announcement for quarter ended March 29, 2026.
Johnson & Johnson 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 fiscal 2026 sales and earnings announcement for quarter ended March 29, 2026
- Exhibit 99.1 contains the detailed financial results and management commentary
Item 8.01 · Other Events
- Quarterly dividend increased 3.1% to $1.34 per share from $1.30
- Indicated annual dividend rises to $5.36 per share from $5.20
- 64th consecutive year of dividend increases, reinforcing J&J’s income-investor profile
- Dividend payable June 9, 2026 to shareholders of record May 26, 2026
Item EX-99.1 · Exhibit EX-99.1
- Q1 sales $24.1B, up 9.9%; adjusted EPS $2.70, down 2.5%, signaling strong top-line growth but earnings pressure
- Net earnings fell 52.4% to $5.235B, while free cash flow declined to approximately $1.5B from $3.379B
- 2026 outlook raised to $100.8B reported sales and $11.55 adjusted EPS at midpoint
- Innovative Medicine operational growth 7.4%, led by oncology and immunology; STELARA reduced growth by approximately 920 basis points
- New ICOTYDE, multiple-myeloma, and MedTech approvals expand growth opportunities; Enterprise Business Review planned for December 8, 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Johnson & Johnson 8-K filings
Get the next JNJ 8-K as it lands
Follow JNJ for push alerts, or ask the research agent what this filing means.